drugset / Trial / NCT04819776

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

NCT04819776

Phase 3 Completed 417 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to investigate the efficacy, safety, and tolerability of iloperidone compared with placebo in treating acute manic or mixed episodes associated with Bipolar I Disorder.

Timeline

Start
2021-03-22
Primary completion
2022-09-07
Completion
2023-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloperidone Small molecule 24 mg Oral

Indications